Methods of treating PRLR positive breast cancer
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMarcus Kelly, Jessica Kirshner, Gavin Thurston
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating prolactin receptor positive breast cancer using an antibody drug conjugate (ADC) comprising an anti-PRLR antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent. In certain embodiments, the anti-PRLR antibody or antigen-binding fragment thereof is conjugated to maytansinoid. In certain embodiments, the method of treating PRLR positive breast cancer includes administering the ADC in combination with one or more chemotherapeutic agents.
Claims34
A method of treating PRLR positive breast cancer, the method comprising co-administering to a patient a therapeutically effective amount of:
- (a) an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to a maytansinoid, wherein the antibody or antigen-binding fragment thereof binds to human prolactin receptor (PRLR);
- and wherein the antibody or antigen binding fragment comprises three heavy chain complementarity determining regions (CDRs) within the heavy chain variable region (HCVR) amino acid sequence and three light chain complementarity determining regions within light chain variable region (LCVR) amino acid sequence of the HCVR/LCVR pair SEQ ID NOs:
- 290/298, wherein between 2 to 3 mg/kg of the ADC is administered and
- (b) fulvestrant, wherein the amount of fulvestrant is 150-250 mg/kg.
A method of treating PRLR positive breast cancer, the method comprising co-administering to a patient a therapeutically effective amount of:
- (a) an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to a maytansinoid, wherein the antibody or antigen-binding fragment thereof binds to human prolactin receptor (PRLR);
- and wherein the antibody or antigen binding fragment comprises an HCDR1 comprising SEQ ID NO:
- 292;
- an HCDR2 comprising SEQ ID NO:
- 294;
- an HCDR3 comprising SEQ ID NO:
- 296;
- an LCDR1 comprising SEQ ID NO:
- 300;
- an LCDR2 comprising SEQ ID NO:
- 302;
- and an LCDR3 comprising SEQ ID NO:
- 304, wherein the antibody concentration is between 2 to 3 mg/kg and
- (b) fulvestrant, wherein the amount of fulvestrant is 150-250 mg/kg.
A method of treating PRLR positive breast cancer in a patient, the method comprising co-administering to a patient a therapeutically effective amount of:
- (a) an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to DM1 through an MCC linker, wherein the antibody or antigen-binding fragment thereof binds to human prolactin receptor (PRLR), wherein the antibody or antigen binding fragment comprises three heavy chain complementarity determining regions (CDRs) within the heavy chain variable region (HCVR) amino acid sequence and three light chain complementarity determining regions within light chain variable region (LCVR) amino acid sequence of the HCVR/LCVR pair SEQ ID NOs:
- 290/298, wherein between 2 to 3 mg/kg of the ADC is administered and
- (b) fulvestrant wherein the amount of fulvestrant is 150-250 mg/kg.
A method of treating PRLR positive breast cancer, the method comprising co-administering to a patient a therapeutically effective amount of:
- (a) an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof conjugated to DM1 through an MCC linker, wherein the antibody or antigen-binding fragment thereof binds to human prolactin receptor (PRLR);
- and wherein the antibody or antigen binding fragment comprises an HCDR1 comprising SEQ ID NO:
- 292;
- an HCDR2 comprising SEQ ID NO:
- 294;
- an HCDR3 comprising SEQ ID NO:
- 296;
- an LCDR1 comprising SEQ ID NO:
- 300;
- an LCDR2 comprising SEQ ID NO:
- 302;
- and an LCDR3 comprising SEQ ID NO:
- 304, wherein the antibody concentration is between 2 to 3 mg/kg and
- (b) fulvestrant, wherein the amount of fulvestrant is 150-250 mg/kg.
Dependencies are inferred from the claim text.